Friday, 20 September 2019 11:55 GMT

Biotech Brief: Global Cellulite Treatment Market Revenues Expanding at Impressive Rate

(MENAFN - GlobeNewsWire - Nasdaq) PALM BEACH, Fla., Aug.14, 2019(GLOBE NEWSWIRE) -- People with cellulite are not as happy as those without cellulite. That may seem to be self-evident, but now it is supported by studies. One such report, a study published by Surgical and Cosmetic Dermatology, found that regarding the psychology of patients with cellulite, nearly 50% of the study population reported dissatisfaction regarding their appearance while nearly 78% reported the need to seek treatment. Women are more susceptible to suffer from cellulite than men. Cellulite is mostly noticeable on the thighs and buttocks, affecting more than 90% of post-adolescent women, although men also can get cellulite. Anotherreportin the Asian Hospital & Healthcare Management (AHH), projected that the Global Cellulite Treatment market revenue is expected to expand at impressive CAGR of 7.7% over the forecast period to reach value of US$ 5,227.7 million by 2028. There are several factors related to cellulite, the major ones include hormonal factors, genetics, diet, sedentary lifestyle, medications, and certain health conditions. At present, according to Grandview Research, the market is segmented into minimally invasive, non-invasive, and topical procedures. The non-invasive segment dominated the market in 2018 and is projected to expand further at the highest CAGR over the forecast through 2026. Active Healthcare – Medical Device companies in the markets this week include: Soliton, Inc. (NASDAQ: SOLY), Medtronic plc (NYSE: MDT), Baxter International Inc. (NYSE: BAX), Boston Scientific Corporation (NYSE: BSX).

The AHHarticleadded: 'Research collaborations and partnerships between research institutes and technology companies is the prominent trend observed in global cellulite treatment market. Non-Invasive segment contributed highest market share and will continue to do so due to focused development of rising prevalence of fat deposition related disorders requiring better treatment options. The U.S. being a high growth market and possess expertise and resources, is expected to continue to dominate the global market. Majority of manufacturers of cellulite treatment are focusing to launch their product in emerging markets due to chances of early approval that by FDA.'

Soliton, Inc. (NASDAQ: SOLY) BREAKING NEWS: Soliton, a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ('MD Anderson'), today announced that the company has treated the first patients in its pivotal cellulite trial.

Dr. Chris Capelli, President, CEO and co-founder of Soliton, commented, 'Patient treatments have now begun at the Chicago site.' He continued, 'It is incredibly exciting to have arrived at this point of the study. A tremendous amount of work goes into preparing for a study of this magnitude and treating the first patients is quite rewarding.'

Cellulite affects up to 90% of women and over a billion dollars per year is spent on treatment in the U.S. Results from our initial proof of concept clinical trial suggest the potential for a new approach to treating cellulite. In the proof of concept trial, the Soliton Rapid Acoustic Pulse ('RAP') device was applied to the surface of the patients' skin for a single 20-minute, non-invasive treatment. The treatments required no anesthesia, caused no bruising, swelling or infection, and were evaluated by the trial participants as a '0' on a pain scale of 0-10 in 97% of the treatments. None of the patients experienced any post-treatment downtime. The Soliton device used in this trial has not been reviewed or cleared by the FDA for marketing and, accordingly, none of the information in this press release is intended to promote the sale or use of the device. The device is investigational and is not available for sale in the United States. Read this and more news for SOLY at:
Recent trading activity and developments in the medical device industry consists of:

Medtronic plc (NYSE: MDT) closed up slightly on Tuesday trading over 2.7 Million shares by the market close. MDT announced this week that it will report financial results for the first quarter of fiscal year 2020 on Tuesday, August 20, 2019. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at . The news release will include summary financial information for the company's first quarter of fiscal year 2020, which ended on Friday, July 26, 2019.

Medtronic will host a webcast at 7:00 a.m. CDT to discuss financial results for its first quarter of fiscal year 2020. The webcast can be accessed at http://investorrelations.medtronic.comon August 20, 2019.

Baxter International Inc. (NYSE: BAX) closed up over 3% on Tuesday trading over 3 Million shares by the market close. Baxter, a leading global medical products company, announced this week it will present at the 2019 Wells Fargo Healthcare Conference in Boston on September 5, 2019. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 1:20 p.m. Eastern Time.

The live webcast of Baxter's presentation can be accessed at and will be available for replay through March 3, 2020.

Boston Scientific Corporation (NYSE: BSX) closed up slightly on Tuesday trading over 3 Million shares by the market close. Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare.

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates and, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press releases issued by Soliton, Inc. by the company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:

Media Contact email: - +1(561)325-8757




Biotech Brief: Global Cellulite Treatment Market Revenues Expanding at Impressive Rate


  Most popular stories  

Day | Week | Month